SIGNIFICANCE OF THE ABCG2 Val12Met POLYMORPHISM IN CORONARY ARTERY DISEASE

Objective. To assess the distribution of ABCG2 Val12Met alleles and genotypes in patients with coronary artery disease (CAD) and determine their association with CAD and hyperuricemia. The study included 197 partici­pants: 102 patients with CAD and 95 apparently healthy controls. The Met allele was detected in 18.6% of patients versus 4.7% of controls and was associated with 4.6-fold higher odds of CAD (OR=4.6; 95%CI:2.28–9.31). The Val/Met genotype occurred in 31.4% and 9.5%, respectively (OR=4.4; 95%CI:2.04–9.38). Among CAD patients, Val/Met was present in 40.0% of subjects with hyperuricemia versus 19.0% of those with normal uric acid levels (OR=2.8; 95%CI:1.12–7.16). ABCG2 Val12Met may therefore represent a potential molecular genetic marker of cardiometabolic risk.